Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

141. Continuous monitoring of glucose for Type 1 Diabetes: a health technology assessment

Ontario. Continuous monitoring of glucose for Type 1 Diabetes: a health technology assessment. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series; 18(2). 2018 Authors' conclusions Continuous glucose monitoring was more effective than self-monitoring of blood glucose in managing type 1 diabetes for some outcomes, such as time spent in the target glucose range and time spent outside the target glucose range (moderate certainty in this evidence). We were less certain (...) Continuous monitoring of glucose for Type 1 Diabetes: a health technology assessment Continuous monitoring of glucose for Type 1 Diabetes: a health technology assessment Continuous monitoring of glucose for Type 1 Diabetes: a health technology assessment Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality

Health Technology Assessment (HTA) Database.2018

142. Continuous monitoring of glucose for Type 1 diabetes: OHTAC recommendation

Continuous monitoring of glucose for Type 1 diabetes: OHTAC recommendation Continuous monitoring of glucose for Type 1 diabetes: OHTAC recommendation Continuous monitoring of glucose for Type 1 diabetes: OHTAC recommendation Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Continuous (...) monitoring of glucose for Type 1 diabetes: OHTAC recommendation. Toronto: Health Quality Ontario (HQO). 2018 Authors' conclusions Health Quality Ontario, under the guidance of the Ontario Health Technology Advisory Committee, recommends publicly funding continuous glucose monitoring in patients with type 1 diabetes who are willing to use continuous glucose monitoring for the vast majority of the time and who meet one or more of the following criteria: • Severe hypoglycemia without an obvious precipitant

Health Technology Assessment (HTA) Database.2018

143. Study of the effect of the herbal composition SR2004 on hemoglobin A1c, fasting blood glucose, and lipids in patients with type 2 diabetes mellitus

Study of the effect of the herbal composition SR2004 on hemoglobin A1c, fasting blood glucose, and lipids in patients with type 2 diabetes mellitus 30271713 2018 11 14 2213-4220 7 3 2018 Sep Integrative medicine research Integr Med Res Study of the effect of the herbal composition SR2004 on hemoglobin A1c, fasting blood glucose, and lipids in patients with type 2 diabetes mellitus. 248-256 10.1016/j.imr.2018.04.002 Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by raised (...) interesting findings relating to the reversal of microvascular phenomena warrant further research to elucidate the mechanisms of action of this novel composition. Chatterji Sumit S Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. Fogel Dov D D.S. Polyclinic, Givat Shmuel, Israel. eng Journal Article 2018 04 30 Netherlands Integr Med Res 101612707 2213-4220 Glucose Herbal Lipids Retinopathy Type 2 diabetes mellitus 2018 01 24 2018 03 23 2018 04 05 2018 10 2 6 0 2018 10 3 6 0 2018 10 3 6 1 ppublish

Integrative medicine research2018 Full Text: Link to full Text with Trip Pro

144. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis.

Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. OBJECTIVE: To evaluate the efficacy and safety of artificial pancreas treatment in non-pregnant outpatients with type 1 diabetes. DESIGN: Systematic review and meta-analysis of randomised controlled trials. DATA SOURCES: Medline, Embase, Cochrane Library, and grey literature up to 2 February 2018. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials in non-pregnant (...) outpatients with type 1 diabetes that compared the use of any artificial pancreas system with any type of insulin based treatment. Primary outcome was proportion (%) of time that sensor glucose level was within the near normoglycaemic range (3.9-10 mmol/L). Secondary outcomes included proportion (%) of time that sensor glucose level was above 10 mmol/L or below 3.9 mmol/L, low blood glucose index overnight, mean sensor glucose level, total daily insulin needs, and glycated haemoglobin. The Cochrane

BMJ2018 Full Text: Link to full Text with Trip Pro

145. Type 2 Diabetes: When Does It Start?

Type 2 Diabetes: When Does It Start? 29732459 2018 11 14 2472-1972 2 5 2018 May 01 Journal of the Endocrine Society J Endocr Soc Type 2 Diabetes: When Does It Start? 476-484 10.1210/js.2018-00071 We aimed to clarify the onset of diabetes. Data from 27,392 nondiabetic health examinees were retrospectively analyzed for a mean of 5.3 years. Trajectories of fasting plasma glucose (FPG), body mass index (BMI), and the single point insulin sensitivity (Si) estimator (SPISE), an index of Si, 10 years (...) before diagnosis of prediabetes (PDM; n = 4781) or diabetes (n = 1061) were separately assessed by a mixed effects model. Diabetes and PDM were diagnosed by the American Diabetes Association definition on the basis of FPG and glycosylated hemoglobin A1c values. In individuals who developed diabetes, mean FPG and BMI were significantly higher ( P < 0.01 each) and SPISE lower than those who did not at -10 years: FPG 101.5 mg/dL vs 94.5 mg/dL, BMI 24.0 kg/m 2 vs 22.7 kg/m 2 , and SPISE 7.32 vs 8.34, P

Journal of the Endocrine Society2018 Full Text: Link to full Text with Trip Pro

146. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.

Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. Importance: The comparative clinical efficacy of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors for treatment of type 2 diabetes is unknown. Objective: To compare (...) the efficacies of SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors on mortality and cardiovascular end points using network meta-analysis. Data Sources: MEDLINE, Embase, Cochrane Library Central Register of Controlled Trials, and published meta-analyses from inception through October 11, 2017. Study Selection: Randomized clinical trials enrolling participants with type 2 diabetes and a follow-up of at least 12 weeks were included, for which SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors were

JAMA2018 Full Text: Link to full Text with Trip Pro

147. Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes.

Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes. Background Childhood overweight is associated with an increased risk of type 2 diabetes in adulthood. We investigated whether remission of overweight before early adulthood reduces this risk. Methods We conducted a study involving 62,565 Danish men whose weights and heights had been measured at 7 and 13 years of age and in early adulthood (17 to 26 years of age). Overweight was defined in accordance with Centers (...) for Disease Control and Prevention criteria. Data on type 2 diabetes status (at age ≥30 years, 6710 persons) were obtained from a national health registry. Results Overweight at 7 years of age (3373 of 62,565 men; 5.4%), 13 years of age (3418 of 62,565; 5.5%), or early adulthood (5108 of 62,565; 8.2%) was positively associated with the risk of type 2 diabetes; associations were stronger at older ages at overweight and at younger ages at diagnosis of type 2 diabetes. Men who had had remission of overweight

NEJM2018

148. Type 2 diabetes can be reversed with very low-calorie diet

Type 2 diabetes can be reversed with very low-calorie diet NIHR DC | Signal - Type 2 diabetes can be reversed with a low-calorie diet Dissemination Centre Discover Portal NIHR DC Discover Type 2 diabetes can be reversed with a low-calorie diet Published on 13 February 2018 Nearly half of people given a formula replacement diet of 830 calories per day for three to five months, followed by food reintroduction, went into remission from type 2 diabetes. They were supported to achieve and maintain (...) weight reduction by primary care nurses or dieticians. This trial involved 298 adults who had been diagnosed with type 2 diabetes within six years. Those that stuck with the program were more likely to lose weight (average 10kg was lost) and to go into remission compared to usual care. More than two-thirds of them were also able to stop both diabetic and high blood pressure tablets. These results were seen after one year. The challenge will be to see if the results can be maintained over the planned

NIHR Dissemination Centre2018

149. Fewer large babies are born to pregnant woman with type 1 diabetes if their glucose was monitored continuously

Fewer large babies are born to pregnant woman with type 1 diabetes if their glucose was monitored continuously NIHR DC | Signal - Fewer large babies are born to pregnant woman with type 1 diabetes if their glucose was monitored continuously Dissemination Centre Discover Portal NIHR DC Discover Fewer large babies are born to pregnant woman with type 1 diabetes if their glucose was monitored continuously Published on 12 December 2017 Pregnant women with type 1 diabetes who used a continuous (...) indicate diabetic control over 12 weeks, only improved slightly. This may be unsurprising because HbA1c results are less reliable in pregnancy and women found it hard to stick to the continuous monitoring protocol. Strict control of blood glucose levels during pregnancy reduces the risk for women with type 1 diabetes, and their babies are less likely to be large or need treatment for low blood glucose. Continuous monitoring provides many readings but requires the user to deliver insulin accordingly

NIHR Dissemination Centre2018

150. Type 2 diabetes is becoming more common in children

Type 2 diabetes is becoming more common in children NIHR DC | Signal - Type 2 diabetes is becoming more common in children Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Type 2 diabetes is becoming more common in children Published on 25 July 2017 The number of children being diagnosed with both type 1 and type 2 diabetes is rising, but new cases of type 2 diabetes, the form associated with being overweight, has risen five-fold in about five years. New analysis in this NIHR (...) -supported study suggest that type 2 diabetes now accounts for up to a third of diabetes diagnoses in children. Amongst 100,000 school age children about six new cases of type 2 diabetes a year could be expected in the 1990s. This increased to about 33 new cases per year by the end of the next decade (2009 to 2013). Data was taken from the UK Clinical Practice Research Datalink, a primary care database of electronic health records. Children who are obese have about a four times greater risk of developing

NIHR Dissemination Centre2018

151. Flu vaccine reduces deaths for people with type 2 diabetes

Flu vaccine reduces deaths for people with type 2 diabetes NIHR DC | Signal - Flu vaccine reduces deaths for people with type 2 diabetes Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Flu vaccine reduces deaths for people with type 2 diabetes Published on 18 October 2016 Flu vaccination helps prevent some deaths, serious strokes, heart failure and pneumonia in people with type 2 diabetes. Vaccination is linked to less hospital admissions for these reasons (...) , but there is no link to rates of admissions for heart attack. The results come from a reliable population-based study that looked back at the general practice and hospital records of almost 125,000 adults with type 2 diabetes in England. Outcome rates were compared between those who had and hadn’t received the flu vaccine over seven successive flu seasons. The researchers carefully adjusted for things like the seasonal change in flu numbers. The findings strongly support current recommendations that people

NIHR Dissemination Centre2018

152. Insulin pumps not much better than multiple injections for intensive control of type 1 diabetes

glucose control. They are expensive though, costing around £2-3,000, with another £1,500 per year in consumables, and have a life span of four to eight years. About 6% of UK adults with type I diabetes use pumps, which is lower than in many countries. Proponents of pumps suggest more people should be offered them. The aim of this study was to compare the effectiveness of pumps with multiple daily injections. What did this study do? The Relative Effectiveness of Pumps Over MDI and Structured Education (...) Insulin pumps not much better than multiple injections for intensive control of type 1 diabetes NIHR DC | Signal - Insulin pumps not much better than multiple injections for intensive control of type 1 diabetes Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Insulin pumps not much better than multiple injections for intensive control of type 1 diabetes Published on 11 July 2017 People with type 1 diabetes offered insulin pumps did not achieve better blood glucose control

NIHR Dissemination Centre2018

153. Continuous insulin pumps may help manage poorly controlled type 2 diabetes

Continuous insulin pumps may help manage poorly controlled type 2 diabetes NIHR DC | Signal - Continuous insulin pumps may help manage poorly controlled type 2 diabetes Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Continuous insulin pumps may help manage poorly controlled type 2 diabetes Published on 18 July 2017 Continuous subcutaneous insulin infusions, or pumps, reduced the amount of daily insulin required by 24 units for people with advanced type 2 diabetes compared (...) to multiple daily insulin injections. Average weight did not differ between treatments. This review compared the two treatments in 590 people from five trials and found that the pumps were linked to slightly better control for people on higher doses of insulin and those with poorer glucose control. However, looking at all the people with diabetes in these studies, there was no difference in overall control between the different forms of treatment. One main challenge in controlling type 2 diabetes is

NIHR Dissemination Centre2018

154. Nine different drug classes reviewed for type 2 diabetes

Nine different drug classes reviewed for type 2 diabetes NIHR DC | Signal - Nine different drug classes reviewed for type 2 diabetes Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Nine different drug classes reviewed for type 2 diabetes Published on 17 January 2017 Metformin worked best at keeping blood sugar levels under control and remains a good first choice as single therapy. Overall, the nine classes of blood sugar-lowering drugs had similar effect on risk of death from (...) cardiovascular causes and overall mortality, though estimates are imprecise because so few people died in these studies. Risk of other side effects, such as weight gain or risk of low blood sugar did vary between treatments. This very large systematic review of 301 trials compared the drugs given alone or in combination to treat type 2 diabetes against each other. The researchers analysed data from direct comparisons and from studies with dummy treatment arms together. Until now it has been unclear

NIHR Dissemination Centre2018

155. Motivational interviewing may encourage healthy eating in people with type 2 diabetes

Motivational interviewing may encourage healthy eating in people with type 2 diabetes NIHR DC | Signal - Motivational interviewing may encourage healthy eating in people with type 2 diabetes Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Motivational interviewing may encourage healthy eating in people with type 2 diabetes Published on 15 March 2016 A motivational communication approach may help people with type 2 diabetes eat more healthily, but may be no better than usual (...) type 2 diabetes that, if not managed well, can cause serious long-term health problems including heart disease, stroke, blindness and amputations leading to disability. Good management includes education for a healthy diet, exercise and maintaining blood glucose levels within safe limits. Motivational interviewing is a counselling approach used to motivate people to change their behaviour, so could be useful in encouraging good diabetes self-management. It typically involves open-ended questions, reflective

NIHR Dissemination Centre2018

156. Education can restore awareness of low blood glucose in people with type 1 diabetes

Education can restore awareness of low blood glucose in people with type 1 diabetes NIHR DC | Signal - Education can restore awareness of low blood glucose in people with type 1 diabetes Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Education can restore awareness of low blood glucose in people with type 1 diabetes Published on 20 October 2015 This systematic review found that a range of educational and technological interventions could help adults with type 1 diabetes (...) regain awareness of when they have low blood glucose (hypoglycaemia). Nearly one in every three adults with type 1 diabetes stops noticing low blood sugar levels. This means they cannot take action quickly to prevent a medical crisis. People with low awareness of their blood sugar levels are six times more likely to have severe hypoglycaemia, which can cause fits and even coma. The authors recommended an approach to restoring awareness that starts with structured teaching about flexible insulin

NIHR Dissemination Centre2018

157. Sulfonylureas can be considered safe for those with type 2 diabetes

Sulfonylureas can be considered safe for those with type 2 diabetes NIHR DC | Signal - Sulfonylureas can be considered safe for those with type 2 diabetes Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Sulfonylureas can be considered safe for those with type 2 diabetes Published on 20 July 2016 This large review finds that sulfonylurea drugs are not associated with an increased risk of death, heart attack or stroke when compared with placebo, diet control or other diabetes (...) drugs. Sulfonylureas are commonly used in the treatment of adults with type 2 diabetes. The drugs in this class are relatively cheap and have been available for many decades, but there have been conflicting views on their safety. The trials in this review were large enough and sufficiently long to pick up relatively rare harmful events like death. Therefore the researchers were confident that, even if there is a small risk, less than one in 200 people treated with sulfonylureas are likely

NIHR Dissemination Centre2018

158. Gender disparities in the associations of behavioral factors, serious psychological distress and chronic diseases with type 2 diabetes screening among US adults

Gender disparities in the associations of behavioral factors, serious psychological distress and chronic diseases with type 2 diabetes screening among US adults 29619411 2018 11 14 2397-0642 3 2018 Global health research and policy Glob Health Res Policy Gender disparities in the associations of behavioral factors, serious psychological distress and chronic diseases with type 2 diabetes screening among US adults. 9 10.1186/s41256-018-0065-z The increasing prevalence of undiagnosed and diagnosed (...) type 2 diabetes (T2D) posed a major challenge for public health and thus screening for T2D becomes essentially important. The social-demographical factors associated with the use of T2D screening have been widely studied, however, little is known about the impact of behavioral factors, mental health and chronic diseases on prevalence of screening, especially by gender and age groups. We investigated the impact of behavioral factors, mental health and chronic diseases across gender and age groups on the usage

Global health research and policy2018 Full Text: Link to full Text with Trip Pro

159. Ertugliflozin l-pyroglutamic acid (Steglatro) - Diabetes Mellitus, Type 2

Ertugliflozin l-pyroglutamic acid (Steglatro) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86938/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report (...) the Fridericia formula R AC Accumulation ratio RH relative humidity RQ (Environmental) Risk Quotient SBP systolic blood pressure SGLT1 sodium-glucose co-transporter 1 SGLT2 sodium-glucose co-transporter 2 SmPC summary of product characteristics TAMC total aerobic microbial count TYMC total combined yeasts/moulds count T2DM type 2 diabetes mellitus t max time to C max UGE urinary glucose excretion UGT uridine 5’-diphospho-glucuronosyltransferase ULN upper limit of normal UV ultraviolet UV-Vis ultraviolet

European Medicines Agency - EPARs2018

160. Ertugliflozin l-pyroglutamic acid / sitagliptin phosphate monohydrate (Steglujan) - Diabetes Mellitus, Type 2

Ertugliflozin l-pyroglutamic acid / sitagliptin phosphate monohydrate (Steglujan) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86941/2018 Committee for Medicinal Products (...) type 2 diabetes mellitus TECOS Trial Evaluating Cardiovascular Outcomes with Sitagliptin T max time to C max TYMC total combined yeasts/moulds count UGE urinary gluclose excretion UGT uridine 5’-diphospho-glucuronosyltransferase UK United Kingdom UKPDS United Kingdom Prospective Diabetes Study ULN upper limit of normal US United States UV ultraviolet UV-Vis ultraviolet-visible Assessment report EMA/86941/2018 Page 7/139 1. Background information on the procedure 1.1. Submission of the dossier The applicant

European Medicines Agency - EPARs2018